Imatinib Mesylate, Gemcitabine, and Capecitabine in Treating Patients With Advanced Solid Tumors

"Dose level Capecitabine~-1 400 mg/m2 bid~0 500 mg/m2 bid~1. 500 mg/m2 bid~2. 600 mg/m2 bid~3. 600 mg/m2 bid~4. 725 mg/m2 bid~5. 725 mg/m2 bid~6. 850 mg/m2 bid~7. 850 mg/m2 bid"

"Dose level Gemcitabine~-1 400 mg/m2 0 450 mg/m2~1. 550 mg/m2~2. 550 mg/m2~3. 675 mg/m2~4. 675 mg/m2~5. 825 mg/m2~6. 825 mg/m2~7. 1000 mg/m2"

"Dose level Imatinib~-1 400 mg/d 0 400 mg/d~1. 400 mg/d~2. 400 mg/d~3. 400 mg/d~4. 400 mg/d~5. 400 mg/d~6. 400 mg/d~7. 400 mg/d"

C-kit mutations will be assessed on existing paraffin-embedded blocks by Polymerase Chain Reaction and direct sequencing of both juxtamembrane domains (exons 9 and 11) and the tyrosine kinase domain (exons 13 and 17). Every ABI sequence will be compared to a NCBI Human KIT gene nucleotide sequence and will be blast using a NCBI Standard Nucleotide Blast Search to determine the presence of mutation within a particular exon.

C-kit mutations will be assessed on existing paraffin-embedded blocks by Polymerase Chain Reaction and direct sequencing of both juxtamembrane domains (exons 9 and 11) and the tyrosine kinase domain (exons 13 and 17). Every ABI sequence will be compared to a NCBI Human KIT gene nucleotide sequence and will be blast using a NCBI Standard Nucleotide Blast Search to determine the presence of mutation within a particular exon.

C-kit mutations will be assessed on existing paraffin-embedded blocks by Polymerase Chain Reaction and direct sequencing of both juxtamembrane domains (exons 9 and 11) and the tyrosine kinase domain (exons 13 and 17). Every ABI sequence will be compared to a NCBI Human KIT gene nucleotide sequence and will be blast using a NCBI Standard Nucleotide Blast Search to determine the presence of mutation within a particular exon.